REGENXBIO Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RGNX research report →
About the company
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases.
- CEO
- Curran Simpson
- IPO
- 2015
- Employees
- 353
- HQ
- Rockville, MD, US
Price Chart
- Market Cap
- $686.54M
- P/E
- -2.37
- P/S
- 7.82
- P/B
- 33.03
- EV/EBITDA
- -3.24
- Div Yield
- 0.00%
- Gross Margin
- -0.14%
- Op Margin
- -292.28%
- Net Margin
- -330.23%
- ROE
- -232.50%
- ROIC
- -92.12%
- Revenue
- $170.44M · 104.54%
- Net Income
- $-193,878,000 · 14.63%
- EPS
- $-3.76 · 18.08%
- Op Income
- $-161,198,000
- FCF YoY
- 28.02%
- 52W High
- $16.19
- 52W Low
- $5.46
- 50D MA
- $8.29
- 200D MA
- $10.41
- Beta
- 0.90
- Avg Volume
- 1.76M
Get TickerSpark's AI analysis on RGNX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | PAKOLA STEVE | other | 36,725 |
| Jul 1, 26 | PAKOLA STEVE | sell | 36,725 |
| Jun 29, 26 | PAKOLA STEVE | sell | 19,608 |
| Jul 1, 26 | PAKOLA STEVE | other | 36,725 |
| May 29, 26 | Tasse Daniel | other | 46,600 |
| May 29, 26 | Tasse Daniel | other | 9,807 |
| May 29, 26 | STUMP DAVID C | other | 46,600 |
| May 29, 26 | STUMP DAVID C | other | 9,807 |
| May 29, 26 | Zachary Jennifer | other | 46,600 |
| May 29, 26 | Zachary Jennifer | other | 9,807 |
Our RGNX coverage
Recent articles, reports, and earnings notes.
No research on RGNX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RGNX report →Similar companies
Peers in the same neighborhood.